[{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Pierre Fabre"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0.57999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II\/ Phase III","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Urovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Urovant Sciences \/ Urovant Sciences"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Ion Channel Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Hmaxi-K","moa":"Maxi-K channel","graph1":"Urology","graph2":"Phase I","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Ion Channel Innovations","highestDevelopmentStatusID":"6","companyTruncated":"Urovant Sciences \/ Ion Channel Innovations"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Dasman Diabetes Institute | Ion Channel Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Hmaxi-K","moa":"Maxi-K channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Dasman Diabetes Institute | Ion Channel Innovations","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Dasman Diabetes Institute | Ion Channel Innovations"}]
Find Clinical Drug Pipeline Developments & Deals by Urovant Sciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
